Research programme: small molecule therapeutics - Global Blood Therapeutics/Syros Pharmaceuticals
Alternative Names: Fetal haemoglobin inducers - Global Blood Therapeutics/Syros Pharmaceuticals; HbF inducers - Global Blood Therapeutics/Syros PharmaceuticalsLatest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Global Blood Therapeutics; Syros Pharmaceuticals
- Class Antianaemics; Small molecules
- Mechanism of Action Gamma-globin expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Beta-thalassaemia in USA (PO)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (PO)
- 16 Oct 2023 Pfizer terminates the GBT Collaboration Agreement with Syros Pharmaceuticals